Paper3733147
The activation of C5 in the fluid phase and in the absence of C3 through the classical pathway of the complement system.
Kitamura H and 2 others. Immunology, 1986. Cited by 9 papers, by iCite.
11 sourcespapers-2026-11-12-0.1.0
Cite this record
ConductScience Library. The activation of C5 in the fluid phase and in the absence of C3 through the classical pathway of the complement system. Papers, record 3733147. Release papers-2026-11-12-0.1.0, 12 Nov 2026. https://conductscience.org/library/papers/3733147
Paper
PubMed's record of the paper, with iCite's citation figures. No abstract is shown.
- Title
- The activation of C5 in the fluid phase and in the absence of C3 through the classical pathway of the complement system.
- PubMed
Topics13
NLM's MeSH indexing of the paper, its major topics first.
| MeSH term | Major |
|---|---|
| Complement Activation | Major topic |
| Complement C3 | Major topic |
| Complement C5 | Major topic |
| Complement Pathway, Classical | Major topic |
| Animals | |
| Antibodies | |
| Complement System Proteins | |
| Dose-Response Relationship, Immunologic | |
| Erythrocytes | |
| Guinea Pigs | |
| Hemolysis | |
| Humans | |
| Magnesium |
Source PubMed
References26
The papers the reference list in PubMed's record names, those in our copy of PubMed, in the list's order.
| Order | PMID | Title | Journal | Year | In Papers | Source |
|---|---|---|---|---|---|---|
| 1 | 5,960,883 | Methods for the separation, purification and measurement of nine components of hemolytic complement in guinea-pig serum. | Immunochemistry | 1966 | https://conductscience.org/library/papers/5960883 | PubMed |
| 2 | 95,812 | Deficiency of the ninth component of complement in man. | J Clin Lab Immunol | 1979 | https://conductscience.org/library/papers/95812 | PubMed |
| 3 | 4,179,470 | The relationship of the hemolytic activity of active C'1s to its TAMe esterase action: a new method of purification and assay. | J Immunol | 1969 | https://conductscience.org/library/papers/4179470 | PubMed |
| 4 | 4,182,367 | The ninth component of human complement: isolation, description and mode of action. | Immunology | 1969 | https://conductscience.org/library/papers/4182367 | PubMed |
| 5 | 4,193,935 | Reactive lysis: the complement-mediated lysis of unsensitized cells. II. The characterization of activated reactor as C56 and the participation of C8 and C9. | J Exp Med | 1970 | https://conductscience.org/library/papers/4193935 | PubMed |
| 6 | 5,470,509 | Lysis of erythrocytes by complement in the absence of antibody. | J Exp Med | 1970 | https://conductscience.org/library/papers/5470509 | PubMed |
| 7 | 4,748,119 | The complement system. | Sci Am | 1973 | https://conductscience.org/library/papers/4748119 | PubMed |
| 8 | 4,213,402 | Studies of complement complex C5b,6 eluted from--EAC-6: reaction of C5b,6 with EAC4b,3b and evidence on the role of C2a and C3b in the activation of C5. | J Immunol | 1974 | https://conductscience.org/library/papers/4213402 | PubMed |
| 9 | 4,214,868 | Molecular analysis of the reaction of C9 with EAC1-8: reaction of C9 with EAC1-8. | J Immunol | 1974 | https://conductscience.org/library/papers/4214868 | PubMed |
| 10 | 1,249,415 | Purification of the sixth and seventh component of human complement without loss of hemolytic activity. | J Immunol | 1976 | https://conductscience.org/library/papers/1249415 | PubMed |
| 11 | 1,218,074 | Trypsin-activated complex of human factor B with cobra venom factor (CVF), cleaving C3 and C5 and generating a lytic factor for unsensitized guinea pig erythrocytes. I. Generation of the activated complex. | Biken J | 1975 | https://conductscience.org/library/papers/1218074 | PubMed |
| 12 | 950,465 | C3 requirements for formation of alternative pathway C5 convertase. | J Immunol | 1976 | https://conductscience.org/library/papers/950465 | PubMed |
| 13 | 823,964 | Third component of human complement: purification from plasma and physicochemical characterization. | Biochemistry | 1976 | https://conductscience.org/library/papers/823964 | PubMed |
| 14 | 322,709 | Purification and structural analysis of the fourth component of human complement. | Biochemistry | 1977 | https://conductscience.org/library/papers/322709 | PubMed |
| 15 | 659,890 | The complex of C5b and C6: isolation, characterization, and identification of a modified form of C5b consisting of three polypeptide chains. | J Immunol | 1978 | https://conductscience.org/library/papers/659890 | PubMed |
| 16 | 106,884 | Fifth component of human complement: purification from plasma and polypeptide chain structure. | Biochemistry | 1979 | https://conductscience.org/library/papers/106884 | PubMed |
| 17 | 7,350,230 | The interaction of C5 with C3b in free solution: a sufficient condition for cleavage by a fluid phase C3/C5 convertase. | J Immunol | 1980 | https://conductscience.org/library/papers/7350230 | PubMed |
| 18 | 6,986,046 | Solubilization of antigen-antibody complexes: a new function of complement as a regulator of immune reactions. | Prog Allergy | 1980 | https://conductscience.org/library/papers/6986046 | PubMed |
| 19 | 6,911,149 | Activation of the fifth and sixth component of the complement system: similarities between C5b6 and C(56)a with respect to lytic enhancement by cell-bound C3b or A2C, and species preferences of target cell. | J Immunol | 1981 | https://conductscience.org/library/papers/6911149 | PubMed |
| 20 | 7,265,179 | Further studies on C9 deficiency. | J Clin Lab Immunol | 1981 | https://conductscience.org/library/papers/7265179 | PubMed |
Cited by4
The papers in our copy of PubMed whose reference list names this one, newest first. iCite, which reads more sources, counts 9 citations.
| PMID | Title | Journal | Year | In Papers | Source |
|---|---|---|---|---|---|
| 41,800,440 | A second generation of C3 humanized rats for preclinical evaluation of human C3 inhibitors. | Blood Vessel Thromb Hemost | 2026 | https://conductscience.org/library/papers/41800440 | PubMed |
| 40,535,418 | Effects of Small Extracellular Vesicles Derived From Mesenchymal Stromal Cells on Acute Kidney Injury: A Rat Ischemia-Reperfusion Model. | Cureus | 2025 | https://conductscience.org/library/papers/40535418 | PubMed |
| 31,196,848 | Absence of complement component 3 does not prevent classical pathway-mediated hemolysis. | Blood Adv | 2019 | https://conductscience.org/library/papers/31196848 | PubMed |
| 3,759,127 | C3-independent immune haemolysis: mechanism of membrane attack complex formation. | Immunology | 1986 | https://conductscience.org/library/papers/3759127 | PubMed |
Genes5
The genes the Gene search release ties to the paper: Swiss-Prot's references first, then PubTator's text mining.
| Gene | NCBI Gene ID | Linked by | In Genes | Source |
|---|---|---|---|---|
| C3 | 718 | PubTator's text mining | https://conductscience.org/library/genes/718 | NCBI Gene |
| C5 | 727 | PubTator's text mining | https://conductscience.org/library/genes/727 | NCBI Gene |
| C5AR1 | 728 | PubTator's text mining | https://conductscience.org/library/genes/728 | NCBI Gene |
| CDK5RAP1 | 51,654 | PubTator's text mining | https://conductscience.org/library/genes/51654 | NCBI Gene |
| CRLS1 | 54,675 | PubTator's text mining | https://conductscience.org/library/genes/54675 | NCBI Gene |
Data dates
The date of each source this release read.
- Trials
- 2026-11-12
- Gene search
- 2026-11-11
- Pipelines
- 2026-09-18
None in this release
- Grants
- Trials
- Comments and corrections
- Drugs
- Data
Sources 11
- ChEMBL, through Open TargetsCC BY-SA 3.0
- ClinicalTrials.govNo license stated
- HGNCCC0
- iCiteCC BY 4.0
- NCBI GenePublic domain (US government)
- NIH RePORTER's grant and paper linksPublic domain
- Open TargetsCC0 1.0
- PMC's ID filePublic domain (US government)
- PubMedNLM's terms
- PubTator 3Public domain
- UniProtCC BY 4.0
Each source's terms
- ChEMBL, through Open TargetsCC BY-SA 3.0, for the parts from ChEMBL. Read on 8 Nov 2026 at https://platform-docs.opentargets.org/licence
- ClinicalTrials.govnone stated
- HGNCCC0: https://www.genenames.org/about/license/
- iCiteCC BY 4.0
- NCBI GeneNone named for the file. NCBI says information created by or for the US government on its site is in the public domain, and asks that NLM be acknowledged: https://www.ncbi.nlm.nih.gov/home/about/policies/
- NIH RePORTER's grant and paper linksPublic domain (NIH RePORTER)
- Open TargetsCC0 1.0. Open Targets asks that users cite its latest paper: Buniello et al. 2025, Open Targets Platform: facilitating therapeutic hypotheses building in drug discovery, Nucleic Acids Research 53(D1):D1467, PMID 39657122. Read on 8 Nov 2026 at https://platform-docs.opentargets.org/licence
- PMC's ID fileNone named for the file. NCBI says information created by or for the US government on its site is in the public domain, and asks that NLM be acknowledged: https://www.ncbi.nlm.nih.gov/home/about/policies/
- PubMedNLM's terms
- PubTator 3Public domain
- UniProtCC BY 4.0. UniProt's licence file: "All databases and documents in the UniProt FTP directory may be copied and redistributed freely, without advance permission, provided that this copyright statement is reproduced with each copy." UniProt asks that users cite its latest paper: The UniProt Consortium, UniProt: the Universal Protein Knowledgebase in 2025, Nucleic Acids Research 53:D609-D617, https://doi.org/10.1093/nar/gkae1010. Read on 9 Nov 2026 at https://www.uniprot.org/help/license
ClinicalTrials.gov's data carry an international copyright outside the United States: https://clinicaltrials.gov/about-site/terms-conditions.
For software
Read this paper from software.
The record and each of its lists are JSON, twenty rows a page. No key.
GET https://conductscience.org/api/papers/v1/3733147
GET https://conductscience.org/api/papers/v1/3733147/references?page=2